A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Status: Recruiting
Location: See all (19) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
• Measurable multiple myeloma (MM).
• Eastern Cooperative Oncology Group performance status of 0-1.
Locations
United States
Alabama
University of Alabama at Birmingham
RECRUITING
Birmingham
Arizona
Mayo Clinic in Arizona - Phoenix
RECRUITING
Phoenix
California
City of Hope Comprehensive Cancer Center
RECRUITING
Duarte
Florida
Mayo Clinic in Florida
RECRUITING
Jacksonville
Georgia
Northside Hospital
RECRUITING
Atlanta
Massachusetts
Beth Israel Deaconess Medical Center
RECRUITING
Boston
Dana-Farber Cancer Institute
RECRUITING
Boston
Minnesota
Mayo Clinic in Rochester, Minnesota
RECRUITING
Rochester
Nebraska
University Of Nebraska Medical Center
RECRUITING
Omaha
New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING
Hackensack
New York
Roswell Park Cancer Institute
RECRUITING
Buffalo
Columbia University Irving Medical Center
RECRUITING
New York
Laura and Isaac Perlmutter Cancer Center
RECRUITING
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Pennsylvania
Local Institution - 0023
WITHDRAWN
Pittsburgh
Tennessee
Tennessee Oncology
RECRUITING
Nashville
Texas
University of Texas MD Anderson Cancer Center
RECRUITING
Houston
Other Locations
Canada
Tom Baker Cancer Center
RECRUITING
Calgary
Princess Margaret Cancer Centre
RECRUITING
Toronto
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-02-22
Estimated Completion Date: 2028-08-01
Participants
Target number of participants: 117
Treatments
Experimental: Arm A: BMS-986393 + Alnuctamab
Experimental: Arm B: BMS-986393 + Mezigdomide
Experimental: Arm C: BMS-986393 + Iberdomide
Experimental: Arm D: BMS-986393 + Elranatamab
Related Therapeutic Areas
Sponsors
Leads: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company